Alkermes plc. Files 8-K on Financials

Ticker: ALKS · Form: 8-K · Filed: 2025-01-13T00:00:00.000Z

Sentiment: neutral

Topics: financial-reporting, 8-k, disclosure

TL;DR

Alkermes dropped an 8-K detailing financial results and other disclosures.

AI Summary

Alkermes plc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures and financial statements and exhibits. The company, formerly known as Antler Science Two Ltd, is incorporated in Ireland and its principal executive offices are located in Dublin.

Why It Matters

This 8-K filing provides crucial updates on Alkermes' financial performance and operational results, which can impact investor decisions and stock valuation.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of financial information and does not appear to contain any immediate negative news or significant changes.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on Alkermes plc.'s results of operations and financial condition, as well as to provide Regulation FD disclosures and financial statements and exhibits.

When was this 8-K filing submitted?

This 8-K filing was submitted on January 13, 2025.

Where is Alkermes plc. incorporated?

Alkermes plc. is incorporated in Ireland.

What were Alkermes plc.'s previous names?

Alkermes plc. was formerly known as Antler Science Two Ltd and Antler Science Two PLC.

What is the SIC code for Alkermes plc.?

The Standard Industrial Classification (SIC) code for Alkermes plc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 551 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2025-01-13 08:41:44

Key Financial Figures

Filing Documents

02 Results of Operations and Financial Conditions

Item 2.02 Results of Operations and Financial Conditions. On January 13, 2025, Alkermes plc (the "Company") made available a copy of the corporate presentation to be displayed during its presentation at the J.P. Morgan Healthcare Conference on January 15, 2025, which includes the Company's current expectation of cash and investments for the year ended December 31, 2024. A copy of the presentation is furnished herewith as Exhibit 99.1.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. The information in Item 2.02 above and in Exhibit 99.1 furnished herewith are incorporated in this Item 7.01 by reference. The information contained in this Form 8-K, including in Items 2.02 and 7.01 above, and in Exhibit 99.1 furnished herewith, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01 Financial Sta tements and Exhibits

Item 9.01 Financial Sta tements and Exhibits. (d) Exhibits EXHIBIT INDEX Exhibit No. Description 99.1 Alkermes plc corporate presentation . 104 Cover page interactive data file (embedded within the Inline XBRL document). 2 SIGNA TURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALKERMES PLC Date: January 13, 2025 By: /s/ David J. Gaffin David J. Gaffin Secretary 3

View on Read The Filing